Renaissance of leptin for obesity therapy

Diabetologia

Volumn 59, Issue 5, 2016, Pages 920-927

  Quarta, Carmelo ^a   Sánchez Garrido, Miguel A ^a   Tschöp, Matthias H ^a,b,c   Clemmensen, Christoffer ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Leptin; Leptin resistance; Leptin sensitivity; Obesity; Pharmacology; Polypharmacy; Review; Type 2 diabetes

Indexed keywords

AMYLIN; FIBROBLAST GROWTH FACTOR 21; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; LEPTIN; METFORMIN;

ENDOPLASMIC RETICULUM STRESS; HUMAN; INFLAMMATION; NONHUMAN; OBESITY; PERSONALIZED MEDICINE; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANIMAL; BODY WEIGHT; DRUG EFFECTS; ENERGY METABOLISM; HOMEOSTASIS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BODY WEIGHT; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LEPTIN; OBESITY; SIGNAL TRANSDUCTION;

EID: 84961216805     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3906-7     Document Type: Review

References (65)

1. van der Klaauw AA, Farooqi IS (2015) The hunger genes: pathways to obesity. Cell 161:119–132
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432
3. Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575
4. Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW (2010) Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 21:643–651
5. Oral EA, Simha V, Ruiz E et al (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570–578
6. Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884
7. Farooqi IS, Matarese G, Lord GM et al (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110:1093–1103
8. Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U (2015) Treatment of obesity with celastrol. Cell 161:999–1011
9. de Git KC, Adan RA (2015) Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obes Rev 16:207–224
10. Pedroso JA, Buonfiglio DC, Cardinali LI et al (2014) Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity. Mol Metab 3:608–618
11. Picardi PK, Caricilli AM, de Abreu LL, Carvalheira JB, Velloso LA, Saad MJ (2010) Modulation of hypothalamic PTP1B in the TNF-α-induced insulin and leptin resistance. FEBS Lett 584:3179–3184
12. Lantz KA, Hart SG, Planey SL et al (2010) Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity 18:1516–1523
13. Byun K, Gil SY, Namkoong C et al (2014) Clusterin/ApoJ enhances central leptin signaling through Lrp2-mediated endocytosis. EMBO Rep 15:801–808
14. Roth JD, Roland BL, Cole RL et al (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 105:7257–7262
15. Müller TD, Sullivan LM, Habegger K et al (2012) Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18:383–393
16. Kim YW, Kim JY, Park YH et al (2006) Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55:716–724
17. Yan C, Yang Y, Saito K et al (2015) Meta-chlorophenylpiperazine enhances leptin sensitivity in diet-induced obese mice. Br J Pharmacol 172:3510–3521
18. Wang L, Barachina MD, Martinez V, Wei JY, Tache Y (2000) Synergistic interaction between CCK and leptin to regulate food intake. Regul Pept 92:79–85
19. Unniappan S, Kieffer TJ (2008) Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats. Am J Physiol Regul Integr Comp Physiol 295:R51–R58
20. Ravussin Y, Leibel RL, Ferrante AW Jr (2014) A missing link in body weight homeostasis: the catabolic signal of the overfed state. Cell Metab 20:565–572
21. Ottaway N, Mahbod P, Rivero B et al (2015) Diet-induced obese mice retain endogenous leptin action. Cell Metab 21:877–882
22. Ozcan L, Ergin AS, Lu A et al (2009) Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9:35–51
23. Cakir I, Cyr NE, Perello M et al (2013) Obesity induces hypothalamic endoplasmic reticulum stress and impairs proopiomelanocortin (POMC) post-translational processing. J Biol Chem 288:17675–17688
24. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D (2008) Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell 135:61–73
25. Hosoi T, Baba S, Ozawa K (2014) Therapeutic potential of flurbiprofen against obesity in mice. Biochem Biophys Res Commun 449:132–134
26. Hosoi T, Yamaguchi R, Noji K et al (2014) Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress. EMBO Mol Med 6:335–346
27. Henstridge DC, Whitham M, Febbraio MA (2014) Chaperoning to the metabolic party: the emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. Mol Metab 3:781–793
28. Kars M, Yang L, Gregor MF et al (2010) Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 59:1899–1905
29. Park SW, Ozcan U (2013) Potential for therapeutic manipulation of the UPR in disease. Semin Immunopathol 35:351–373
30. Ma X, Xu L, Alberobello AT et al (2015) Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab 22:695–708
31. Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445
32. Valdearcos M, Xu AW, Koliwad SK (2015) Hypothalamic inflammation in the control of metabolic function. Annu Rev Physiol 77:131–160
33. Thaler JP, Yi CX, Schur EA et al (2012) Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 122:153–162
34. Kleinridders A, Schenten D, Konner AC et al (2009) MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 10:249–259
35. Milanski M, Degasperi G, Coope A et al (2009) Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 29:359–370
36. Gao Y, Ottaway N, Schriever SC et al (2014) Hormones and diet, but not body weight, control hypothalamic microglial activity. Glia 62:17–25
37. De Souza CT, Araujo EP, Bordin S et al (2005) Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 146:4192–4199
38. Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, Kahn BB (2008) Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem 283:14230–14241
39. Thaler JP, Guyenet SJ, Dorfman MD, Wisse BE, Schwartz MW (2013) Hypothalamic inflammation: marker or mechanism of obesity pathogenesis? Diabetes 62:2629–2634
40. Kim JG, Suyama S, Koch M et al (2014) Leptin signaling in astrocytes regulates hypothalamic neuronal circuits and feeding. Nat Neurosci 17:908–910
41. Yu Y, Wu Y, Szabo A et al (2013) Teasaponin reduces inflammation and central leptin resistance in diet-induced obese male mice. Endocrinology 154:3130–3140
42. Posey KA, Clegg DJ, Printz RL et al (2009) Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296:E1003–E1012
43. Jang PG, Namkoong C, Kang GM et al (2010) NF-κB activation in hypothalamic pro-opiomelanocortin neurons is essential in illness- and leptin-induced anorexia. J Biol Chem 285:9706–9715
44. Oh IS, Thaler JP, Ogimoto K, Wisse BE, Morton GJ, Schwartz MW (2010) Central administration of interleukin-4 exacerbates hypothalamic inflammation and weight gain during high-fat feeding. Am J Physiol Endocrinol Metab 299:E47–E53
45. Benzler J, Ganjam GK, Pretz D et al (2015) Central inhibition of IKKβ/NF-κB signaling attenuates high-fat diet-induced obesity and glucose intolerance. Diabetes 64:2015–2027
46. Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S (2001) Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metab Clin Exp 50:1457–1461
47. Glueck CJ, Fontaine RN, Wang P et al (2001) Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metab Clin Exp 50:856–861
48. Fruehwald-Schultes B, Oltmanns KM, Toschek B et al (2002) Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metab Clin Exp 51:531–536
49. Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP (2011) The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metab Clin Exp 60:327–334
50. Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ (2000) Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res 8:530–539
51. Aronne L, Fujioka K, Aroda V et al (2007) Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977–2983
52. Ravussin E, Smith SR, Mitchell JA et al (2009) Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17:1736–1743
53. Mietlicki-Baase EG, Olivos DR, Jeffrey BA, Hayes MR (2015) Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake. Am J Physiol Endocrinol Metab 308:E1116–E1122
54. Turek VF, Trevaskis JL, Levin BE et al (2010) Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 151:143–152
55. Sinha G (2014) Leptin therapy gains FDA approval. Nat Biotechnol 32:300–302
56. Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P (2016) Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol 9:59–68
57. Rodriguez AJ, Mastronardi CA, Paz-Filho GJ (2015) New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag 11:1391–1400
58. Finan B, Clemmensen C, Muller TD (2015) Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418P1:42–54
59. Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749–757
60. Clemmensen C, Chabenne J, Finan B et al (2014) GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63:1422–1427
61. Cegla J, Troke RC, Jones B et al (2014) Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63:3711–3720
62. Tan TM, Field BC, McCullough KA et al (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62:1131–1138
63. Finan B, Yang B, Ottaway N et al (2012) Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18:1847–1856
64. Simonds SE, Cowley MA (2013) Hypertension in obesity: is leptin the culprit? Trends Neurosci 36:121–132
65. Chan JL, Koda J, Heilig JS et al (2015) Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol. doi:10.1111/cen.12980